CRI iAtlas Expands to Interactive Analysis of Data on Immunotherapy Treatments
at the Institute for Systems Biology
News
CRI iAtlas Expands to Interactive Analysis of Data on Immunotherapy Treatments
CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors.
ISB Researchers Among Recipients of AACR Team Science Award
The American Association for Cancer Research (AACR) has recognized The Cancer Genome Atlas (TCGA) project with the 2020 AACR Team Science Awards. Award recipients include Dr. Ilya Shmulevich, ISB professor and head of the Shmulevich Lab; ISB senior research scientist Dr. Vésteinn Þórsson; and former Shmulevich Lab members Drs. Brady Bernard and Theo Knijnenburg.
Unveiling the Guerrilla Warfare Tactics of Mycobacterium Tuberculosis
ISB researchers have unveiled new insights on how Mycobacterium tuberculosis, the pathogen that causes tuberculosis, enters and exits a dormant state in human hosts. About a quarter of the world’s population has latent TB, so these important findings will enable and accelerate the discovery of more effective TB drugs.
Sanger Institute’s COSMIC database expands cancer cloud capabilities at the Institute for Systems Biology
The Wellcome Trust Sanger Institute released this news on Feb. 20, 2017. See original release… FOR IMMEDIATE RELEASE The Wellcome Trust Sanger Institute’s Catalog of Somatic Mutations in Cancer (COSMIC) team announces a new agreement to provide their data to the U.S.-based Institute for Systems Biology (ISB). COSMIC is an expert-curated cancer mutation database, and is the world’s largest and most comprehensive resource for exploring the impact of somatic mutations…
Comprehensive study of esophageal cancer reveals several molecular subtypes, provides new insight into increasingly prevalent disease
The Cancer Genome Atlas Research Network recommends clinical trials organizers and drug manufacturers focus on newly discovered molecular subtypes GRAND RAPIDS, Mich., Jan. 4, 2017 –– A comprehensive analysis of 559 esophageal and gastric cancer samples, collected from patients around the world, suggests the two main types of esophageal cancer differ markedly in their molecular characteristics and should be considered separate diseases. The study, published today in Nature from The…
ISB Gets $3.4M NIH Extension for Cancer Genomics Cloud
FOR IMMEDIATE RELEASE ISB Receives $3.4 Million Extension to NIH Contract to Continue Development of ‘Cancer Genomics Cloud’ with Google and CSRA SEATTLE, Oct. 21, 2016 – Institute for Systems Biology (ISB) has received a $3.4 million, one-year extension to an existing federally-funded contract from the National Cancer Institute (NCI), National Institutes of Health (NIH). This follows the completion of the initial two-year, $6.5 million contract during which ISB developed…